Stepwise regression models for the C–CO₂ rates at the initial (T₀) and final (T₁₂₀; delta values) conditions of incubations. by Daniel Cuevas-Lara (12188972)

Subjects:

PCA of the dissolved nutrients’ deltas at T₁₂₀ in the water samples incubations. by Daniel Cuevas-Lara (12188972)

Subjects:

Upper quartile of district towns evaluated by the SD-TOPSIS technique ‐ combination of A, B1, B2 and C1. by Roman Vavrek (13200141)

Lower quartile of district towns evaluated by the SD-TOPSIS technique ‐ combination of A, B1, B1 and C1. by Roman Vavrek (13200141)

Distribution of final population size (A) and mean change in mean MSI over time (B) over 100 simulations for each parameter set shown in Table 3 in the absence of weevils (left) an... by Alexandra M. Campbell (3284094)

Source data for Fig 4C. by Isabel Raposo (21615517)

Source data for Fig 1C. by Isabel Raposo (21615517)

Growth kinetics of YFV-17D/Asibi chimeras in C6/36 cells. by Anja vom Hemdt (19787189)

Subjects:

Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage. by Verónica M. Negrón-Pérez (20691412)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

“…However, there is concern that by neutralizing the SARS-CoV-2 virus, nMAbs may decrease the availability of antigens to the immune system, potentially impairing the endogenous polyclonal immune response and decreasing long-term immune protection.…”

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)